Image de couverture de livre

Bimekizumab efficacy and safety reaffirmed in Chinese patients, with notable safety findings

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Yoo Sang Baek, Seong Jin Jo
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	Journal of the European Academy of Dermatology and Venereology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Evaluating the safety and efficacy of biologics in psoriatic patients with malignancies: Insights and future directions
par: Sebastian Yu, et autres
Publié: (2024)

Comments on ‘Evaluating the safety and efficacy of biologics in psoriatic patients with malignancies: Insights and future directions’
par: M. Magnano, et autres
Publié: (2024)

Abrocitinib for prurigo nodularis: Clinical efficacy and safety profile
par: Changchun Wang, et autres
Publié: (2024)

Long‐term safety and efficacy in paediatric psoriasis: Remaining challenges
par: Catherine Droitcourt, et autres
Publié: (2026)

Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real‐world study
par: Annunziata Raimondo, et autres
Publié: (2024)

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II
par: Thrasyvoulos Tzellos, et autres
Publié: (2026)

Beta‐blockers efficacy and safety in the treatment of PHACE syndrome: A systematic review
par: Eitan Pirov, et autres
Publié: (2025)

Real‐world efficacy and safety of ritlecitinib in alopecia areata: A single‐centre experience
par: Youyu Sheng, et autres
Publié: (2025)

Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies
par: H. Bachelez, et autres
Publié: (2024)

Topical corticosteroids in the era of new topical therapies: Balancing efficacy and safety for long‐term use
par: Alexander Egeberg, et autres
Publié: (2024)

Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
par: M. Senna, et autres
Publié: (2024)

Dual impact of smoking cessation and post‐cessation weight change on psoriasis
par: Seong Rae Kim, et autres
Publié: (2025)

Beyond events per 100 patient‐years: Interpreting 6‐year upadacitinib safety in atopic dermatitis
par: Anxin Wen
Publié: (2025)

Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
par: B. M. Piraccini, et autres
Publié: (2024)

Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study
par: A. Bagit, et autres
Publié: (2024)

Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials
par: April W. Armstrong, et autres
Publié: (2025)

Efficacy and safety of oral abrocitinib monotherapy in pityriasis rubra pilaris
par: Ying Li, et autres
Publié: (2024)

Efficacy and safety of bimekizumab in the treatment of genital psoriasis: A case series
par: L. Bettolini, et autres
Publié: (2024)

Critical methodological enhancements for JAK inhibitor safety studies in atopic dermatitis
par: Zheying Huang, et autres
Publié: (2025)

Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
par: C. Tziotzios, et autres
Publié: (2025)

Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’
Publié: (2025)

Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
par: Chaofan Wang, et autres
Publié: (2025)

Efficacy and safety of dupilumab in Hailey–Hailey disease: A multicentre cohort study
par: N. Oillarburu, et autres
Publié: (2025)

Real‐world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate‐to‐severe plaque psoriasis
par: Natalia Rompoti, et autres
Publié: (2024)

Translating 6‐year trial safety data of upadacitinib in atopic dermatitis into clinical practice
par: Lian F. van der Gang, et autres
Publié: (2026)

Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis
par: Lian F. van der Gang, et autres
Publié: (2026)

Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
par: A. Mourtada, et autres
Publié: (2025)

Single‐cell transcriptomic analysis of GPP patients treated with IL‐12/23 or IL‐17A blockade
par: Soyoung Jeong, et autres
Publié: (2025)

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta‐analysis of phase III trials
par: Laura Calabrese, et autres
Publié: (2025)

Reply to ‘Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa’ by Holgersen et al.
par: Fabrizio Martora, et autres
Publié: (2024)

Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry
par: Filip Rob, et autres
Publié: (2025)

Effectiveness, safety and reasons for discontinuation of sonidegib for patients with locally advanced basal cell carcinoma: A real‐word evidence analysis from the French national registry CARADERM
par: Nicole Basset‐Seguin, et autres
Publié: (2024)

Efficacy and safety of nemolizumab in paediatric atopic dermatitis: A 24‐week real‐world case series
par: Yohei Takahashi, et autres
Publié: (2025)

Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: Real‐world data from a multicentre study
par: Vasiliki Nikolaou, et autres
Publié: (2024)

Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study
par: B. King, et autres
Publié: (2025)

Efficacy and safety of tozorakimab in moderate‐to‐severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER‐2)
par: J. I. Silverberg, et autres
Publié: (2024)

Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years
par: Melinda J. Gooderham, et autres
Publié: (2026)

Trichoscopic findings in patients using eyelash extensions: A multicentre retrospective analysis of 51 cases
par: Luciana D'avila, et autres
Publié: (2024)

Balancing efficacy and patients experience: A cautious perspective on simulated daylight PDT for superficial BCC
par: Davis Yung Chan, et autres
Publié: (2025)

Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real‐world retrospective study from Spain and systematic review of the published data
par: J. Cañueto, et autres
Publié: (2024)